Ildong Pharmaceuticals Obesity Treatments — From GLP-1 Mechanisms to Weight Reduction, Oral Obesity Drugs

Many people have the thought that they need to lose weight swirling in their heads, but when it actually comes time to adjust their diet or start exercising, they often feel like they're facing a dark void. Especially in the clinic, we frequently see patients who suffer from biological hunger that willpower alone cannot solve. In situations like these, recent news about oral obesity treatments that have been generating buzz lately will likely come as a new hope for many.

How Oral Obesity Drug Candidates Work

The new drug candidate ID110521156 recently announced by the Il-dong Pharmaceutical Group belongs to a class of drugs you may have heard of called GLP-1 receptor agonists. Let me easily explain what this ingredient does in our bodies. Our bodies have a hormone called GLP-1 that helps with the synthesis and secretion of insulin and lowers blood sugar levels.

This hormone doesn't just regulate blood sugar—it also modulates gastrointestinal motility and sends appetite-suppressing signals to the brain. In other words, it makes you feel less hungry and feel satiety faster, naturally reducing food intake. The most notable feature is that it is being developed as an oral formulation, meaning a pill you take by mouth rather than an injection.

Weight Loss Results Seen in Phase 1 Clinical Trials

Let me share information about the actual effects that many of you are curious about. According to Il-dong Pharmaceutical's Phase 1 trial data, administration of this drug candidate showed up to 13.8% weight loss after just 4 weeks. This means even as an oral medication, it demonstrated quite a significant reduction.

What is particularly noteworthy is the drug's persistence. Single ascending dose (SAD) test results showed that efficacy concentrations were maintained in the bloodstream for up to 24 hours. This demonstrates pharmacokinetic characteristics that allow for once-daily dosing. Additionally, it is known that even with repeated dosing, the drug does not excessively accumulate in the body and is not affected by food, suggesting high ease of use.

Advantages of Oral Formulation Compared to Injectables

Most existing obesity treatments have been injectable. The fear of being stabbed with a needle every time and the hassle of storage created a high psychological barrier. However, if they can be changed to oral form like the drug Il-dong Pharmaceutical is developing, accessibility improves dramatically.

Of course, there's more meaning to "convenient" than just ease. If the psychological stress felt by patients decreases, treatment adherence improves, which is highly likely to lead to long-term weight management success. However, please keep in mind that since this is still in Phase 1 clinical trials, additional verification processes for safety and tolerability are needed before actual market launch.

Standards and Environment for Viewing Obesity

The reason we are interested in treatments is because obesity is not simply an appearance issue but a disease. According to one study, Korea is no exception, with a significant portion of the adult population falling into this category when obesity is defined as having a body mass index (BMI) of 25 kg/m² or higher.

When BMI increases, it's not just weight that goes up—risks of various complications like metabolic syndrome, hypertension, and diabetes also rise together. That's why rather than desperately starving yourself with a diet, it's important to accurately understand your body's metabolic state and receive appropriate medical assistance that matches it. Treatments can serve as a supportive tool in that process.

The Perspective on Obesity and Metabolism in Korean Medicine

As a Korean medicine doctor, I don't view obesity simply as "fat that comes from overeating." When I observe the constitutions of patients I see in the clinic, some are in a Giheo (氣虛, qi deficiency) state where their metabolism has stalled due to lack of energy, while others are in a Daepsip (痰濕, phlegm-dampness) state where waste products have accumulated in the body.

While Western medicine suppresses appetite through specific pathways like GLP-1 hormones, Korean medicine treatment focuses on boosting whole-body metabolism to create a body that can burn energy on its own. Unreasonable weight loss that doesn't suit your constitution can actually reduce muscle mass and lower basal metabolic rate, causing the yo-yo effect. That's why I always emphasize a "constitution-customized approach."

Healthy Weight Loss Tips to Start Today

While waiting for new medications or undergoing treatment, let me point out some habits you can start implementing right away.

• Develop the habit of chewing slowly. It takes time for the brain to feel satiety. Chewing more than 20 times per bite naturally promotes GLP-1 hormone secretion and helps prevent overeating.

• Try eating a protein-focused breakfast. Getting enough protein in the morning greatly helps reduce phantom hunger at lunch and dinner.

• Make sure to get enough sleep. When you don't sleep enough, leptin—the hormone that suppresses appetite—decreases, and ghrelin, which makes you feel hungry, increases, making diets much harder.

Dieting isn't simply a game of reducing numbers; it's a process of restoring your body's broken balance. Rather than rushing, listening to the signals your body sends and moving forward slowly is ultimately the fastest path.

If managing diet and exercise on your own feels too overwhelming, or if you're concerned about constitutionally low metabolism, try the Baekrok Gambi-jung program. With customized prescriptions that consider individual constitution and metabolic state added in, you can expect a much smoother and healthier outcome. Please give it a try and feel free to let us know how your body has changed when you come in for your next visit.

---

References

• Pharmacotherapy of Obesity with New Drugs

• KoreaMed Synapse

• Il-dong Pharmaceutical "Oral Obesity Drug Candidate Shows Maximum 13.8% Weight Loss in 4 Weeks"

• Il-dong Pharmaceutical Re-merges with Subsidiary Unobia... R&D Speed to Accelerate